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A B S T R A C T
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a rare familial seizure disorder caused
by mutations in at least two different subunit genes of the neuronal nicotinic acetylcholine receptor
(nAChR), CHRNA4 and CHRNB2. ADNFLE was initially described as a ‘‘pure’’ seizure disorder with a mostly
benign course. We have analysed the clinical features of 19 ADNFLE families from 12 countries with a
total of 150 patients and grouped them with respect to their nAChR mutations. These data suggest that
certain nAChR mutations might be associated with an increased risk for major neurological symptoms
such as mental retardation, schizophrenia-like symptoms or marked cognitive deﬁcits, but the risk for
these disorders seems to be low for most other ADNFLE mutations. The functional data conﬁrm that the
mutations differ from each other with respect to the size of their gain-of function effects and other
biopharmacological characteristics although these functional changes are not predictive for the severity
of the clinical phenotype.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsies affect about 1% of the population, rendering it one of
the most common neurological disorders. Most non-lesional
epilepsies arise on an oligogenic or polygenic background, but
several seizure disorders are known to segregate in a Mendelian
fashion. These rare monogenic epilepsies are valuable models for
scientiﬁc approaches and have already helped to uncover parts of
the various pathomechanisms underlying epileptogenesis. Auto-
somal dominant nocturnal frontal lobe epilepsy (ADNFLE) has a
special role within this group of monogenic epilepsies because it
was the ﬁrst epilepsy in humans for which speciﬁc mutations were
identiﬁed. So far, mutations in at least two genes, CHRNA4 and
CHRNB2 encoding the a4 and b2 subunits of the neuronal nicotinic
acetylcholine receptor (nAChR), are known to give rise to
ADNFLE.1,2 These mutations cause a clinical phenotype that was
initially described as a ‘‘pure’’ epilepsy characterized by nocturnal
seizures that arise mostly from non-REM sleep. In the original
family 27 individuals were affected and, except for the seizures, no
neurological symptoms, psychiatric disturbances or mental
deﬁciencies were reported.3 Subsequent studies indicated that
borderline intelligence or mild deﬁcits in executive tasks are not
uncommon in ADNFLE patients.4 However, major neurological
features such as schizophrenia-like symptoms, mental retardation* Corresponding author. Tel.: +49 89 5160 4468; fax: +49 89 5160 4470.
E-mail address: Ortrud.Steinlein@med.uni-muenchen.de (O.K. Steinlein).
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doi:10.1016/j.seizure.2011.10.003or cognitive deﬁcits have been described only in a few families.5–10
So far it is unknown if these additional features occur by chance, or
if they are indeed causally related to speciﬁc nAChR mutations. The
systematic analysis of the clinical variability presented here
suggests that the risk for additional major neurological and
psychiatric features might be increased for ADNFLE patients with
certain nAChR mutations but rare for the carriers of most other
mutations. The functional studies show that ADNFLE mutations
differ from each other with respect to their biopharmacological
characteristics but that no obvious correlation can be detected
between the severity of the clinical phenotypes and the respective
changes in receptor function.
2. Methods
2.1. Subjects
Clinical data from 20 ADNFLE families with known nAChR
mutations were either taken from the histories of families
diagnosed in our lab (Munich) or collected by reviewing the
relevant literature (for references see Table 1). The study protocol
was approved by the institutional review board and informed
consent was given from the participants.
2.2. Mutation construct
CHRNA4 and CHRNB2 mutations were introduced by PCR-based
site-directed mutagenesis (QuikChange II site-directed mutagene-vier Ltd. All rights reserved.
Table 1
Summary of clinical data for ADNFLE families.
Gene Mutation Ethnic origin Number of clinically affected
individuals (f/m)
Neurological/psychiatric features
other than NFLE (n/t)
Antiepileptic drug treatment (n)/sei-
zure severity (n)/drug efﬁciency (n)
References
CHRNA4 S248F (S280F) British-Australian 27 (18/9) CBZ average 690mg (NA), MD (11)/
controlled in most patients (NA)
1,16–18
Spanish 11 (7/4) CBZ 600–1000mg (4), VPA 700mg (1),
NT (2), NA (4)/controlled (6), poorly
controlled (2)
Norwegian 22 (10/12) Mild mental retardation (1/22)
Psychiatric disorder, unclassiﬁed (1/22)
NA/controlled (10), uncontrolled (1),
SRI (6), NA (5)
Scottish 7 (4/3) Psychological problems (NA) NA (1), NT (6)/SRI (6), severe (1)
S252L (S284L) Japanese 5 (2/3) Mild mental retardation (3/5)
Early childhood onset of epilepsy (3/5)
CBZ NA (1), MD (2), NT (1), NA (1)/
controlled (1), SRI (1), poorly controlled
(2), NA (1)
6–8,23,25
Lebanese 2 (1/1) Low average intellect (1/2)
Early childhood onset of epilepsy (2/2)
NA/poorly controlled (1), NA (1)
Korean 9 (7/2) Mild to moderate mental retardation (7
out of 9 available for testing)
CBZ (1), MD (5), NT (1), NA (2)/SRI (1),
improvement (3), poorly controlled (3)
Polish 3(1/2) Early childhood onset of epilepsy (2/3) MD (2), NT (1)/poorly controlled (3)
776ins3 (865-873insGCT) Norwegian 11 (5/6) Schizophrenia (1/11)
Negative symptoms of schizophrenia
(1/11)
Recurrent psychosis (1/11)
Psychiatric disorder, unspeciﬁed (3/11)
(5 family members were not available
for testing)
NA 5,9
T265I (T293I) German 2 (0/2) CBZ 2400mg (1), CBZ NA (1)/
improvement (1), poorly controlled (1)
19
R308H (R336H) Chinese 1 (0/1) NA MD (1)/poorly controlled (1) 13
CHRNB2 V287L Italian 8 (2/6) CBZ 400–800mg (6), NT (2)/controlled
(6), SRI (1), mild (1)
2,22
V287M Scottish 10 (6/4) Psychological problems mentioned,
numbers not speciﬁed
CBZ NA (4), MD (3), NT (3)/SRI (NA),
poorly controlled (1)
18,20,21
Spanish 6 (3/3) CBZ NA (2), PB 150mg (1), NT (3), NA
(1)/SRI (1), improved (1), controlled (2),
poorly controlled (1), NA (1)
L301V Turkish Cypriot 3 (2/1) CBZ NA (1), NT (2)/SRI (1), mild (1)
poorly controlled (1)
15
V308A Scottish 5 (4/1) LTG NA (1)/controlled (1) 15
German 4 (2/2) CBZ NA (2)/controlled (2)
I312M English 2 (2/0) Low average intellect with signiﬁcant
memory deﬁcits (verbal) (2/2)
MD (2)/controlled (2) 10,24
Korean 2 (2/0) Psychiatric episode with delusional
ideas (1/2)
Normal intelligence with moderate
memory deﬁcits (verbal) (1/2)
Normal intelligence with signiﬁcant
memory deﬁcits (verbal/visual) (1/2)
NA
CHRNA2 I279N Italian 10 (8/2) NA NA/controlled (2), poorly controlled (8) 14
ADNFLE mutations frequently associated with additional major neurological or psychiatric symptoms are given in bold. Mutations are named as in the original references, for CHRNA4 numberings according to reference sequences
(NP_000735.1, NP_000739.1) are given in brackets; NA, data not available; NT, not currently treated; n, number of patients; f/m, female/male; n/t, number of total; MD, patients withmore than one drug; SRI, spontaneous remission
or improvement. Antiepileptic drugs (number of patients given in brackets): CBZ, carbamazepin; PB, phenobarbital; PHT, phenytoin; LTG, lamotrigine.
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O.K. Steinlein et al. / Seizure 21 (2012) 118–123120sis Kit, Stratagene Europe) into full-length cDNAs as previously
described.11 The correct sequences were conﬁrmed by direct
sequencing.
2.3. Functional studies
Xenopus oocytes were isolated and selected as previously
described.11 Brieﬂy, oocytes were harvested from mature Xenopus
females following animal ethic rules of Geneva canton,
Switzerland. Oocytes were isolated by mechanical and enzymatic
action using type I collagenase (Sigma, Basel Switzerland) at 0.2%
in a medium deprived of calcium. Stage V and VI oocytes were
placed in 96 wells microtiter plates (NUNC) in BARTH medium that
contained 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 10 mM HEPES,
0.82 mM MgSO47H2O, 0.33 mM Ca(NO3)24H2O, 0.41 mM
CaCl26H2O, adjusted to pH 7.4 with NaOH and complemented
with kanamycin (20 mg/ml), penicillin (100 U/ml) and streptomy-
cin (100 U/ml). Nuclear injections of 2 ng of cDNAs containing in
equal ratios the genes of interest were performed with a robot,12
and cells were subsequently maintained at 18 8C.
2.4. Recording of nAChR properties
Electrophysiological properties of oocytes were determined
two to ﬁve days after cDNA injection by automated two electrode
voltage clamp. During recording oocytes were continuously
superfused with OR2 (control medium) that contained 82.5 mM
NaCl, 2.5 mM KCl, 2.5 mM CaCl2, 1 mM MgCl2, 5 mM HEPES,
adjusted to pH 7.4 with NaOH. Unless otherwise stated the holding
potential was 100 mV and experiments were performed at 18 8C.
Data were ﬁltered at 10 Hz and digitized at 100 Hz with an analog
to digital converter (National Instrument). Concentration–activa-
tion curves were ﬁtted using a Hill equation in the form: Y = 1/
1 + (EC50/x)
nH where: y = the fraction of evoked current, EC50 = con-
centration for 50% activation of the high afﬁnity, nH = the apparent
cooperativity for the high afﬁnity, x = agonist concentration. For
statistical analysis the unpaired, two-tailed Student’s t-test was
computed either with Excel (Microsoft) or Matlab (mathworks
Inc.).
3. Results
3.1. Clinical ﬁndings
The clinical information of 20 ADNFLE families from 13
countries with a total of 150 patients is summarized in Table 1.
More females than males were affected by nocturnal frontal lobe
epilepsy (total, 86 versus 64, CHRNA4, 55 versus 45; CHRNB2, 23
versus 17; CHRNA2, 8 versus 2). The known mutational spectrum in
ADNFLE includes ﬁve CHRNA4 and four CHRNB2 mutations (Fig. 1).
CHRNA4 mutations are located within or directly adjacent to the
second transmembrane domain (TM2), while CHRNB2 mutations
are equally distributed between TM2 and TM3. An exception isFig. 1. Position of ADNFLE mutations in CHRNA4 and CHRNB2. Wild type amino acids are u
see legend of Table 1.CHRNA4-R308H, a recently published but not yet functionally
characterized mutation in the second intracellular loop.13 A single
CHRNA2 mutation was described in a family with a clinical
phenotype resembling ADNFLE.11,14 Three CHRNA4 mutations
(776ins3, T265I, R308H) and three CHRNB2 mutations (V287L,
L301V, V308A) have each been found only in a single family, while
two CHRNA4 mutations (S248F, S252L) were detected in four
families each, and two (CHRNB2-V287M, CHRNB2-I312M) in two
families each. For most patients with CHRNA4 mutations S248F and
T265I1,15–19 as well as CHRNB2 mutations V287L, V287M, L301V,
and V308A15,18,20–22 no additional major neurological or psychiat-
ric features were reported. A detailed neuropsychological assess-
ment in 11 patients with three of the above mentioned mutations
(S252L, S248F, T265L) showed borderline intelligence but no
mental retardation in 45% of them and mild deﬁcits in executive
functions in all 11 patients.4 Severe additional neurological or
psychiatric features were diagnosed in most carriers of CHRNA4
mutations S252L and 776ins3,5–9,23 and CHRNB2 mutation
I312M.10,24 The CHRNA4 mutation S252L was the only one that
showed an unusual age of onset in 7/19 patients with seizures
starting as early as six months of age, while the average age of
onset for all other mutations was mostly within the second half of
the ﬁrst decade or in the second decade. Only very few patients
with mutations other than S252L were reported to have an earlier
age of onset.3,5 Additional major neurological and psychiatric
features tended to be the same with a given mutation but different
between mutations. Mental retardation was the main additional
symptom described in 10/19 carriers of CHRNA4 mutation S252L,6–
8,23,25 while at least 6/11 affected family members in the CHRNA4-
776ins3 family had serious psychiatric problems including
schizophrenia-like symptoms (four additional affected individuals
from this family refused to be questioned about psychiatric
problems).9 The CHRNB2 mutation I312M was associated with
speciﬁc cognitive defects affecting mostly verbal memory in all
affected members from the two families known to carry this
mutation10,24 (Table 1).
3.2. Electrophysiological analysis
The normalized dose-response curve of the wildtype a4b2
receptors showed a very low sensitivity for acetylcholine for doses
up to 1 mM. Concentrations above 1 mM elicited currents with a
steep increase in amplitude with a maximum reached at 300 mM.
In accordance to previous published studies the results were best
ﬁtted with the sum of two empirical Hill equations.15 Compared to
the wildtype the two mutations a4S248F/b2 and a4S252L/b2
showed a much higher afﬁnity for acetylcholine, which was most
pronounced in the latter mutation. Referring to the EC50H of the
mutated receptors (0.8 for a4S248F/b2 and 0.75 for a4S252L/b2)
they differed markedly from that of the wildtype receptor (8.5).
Nonetheless the Hill coefﬁcients for the high-afﬁnity state as well
as that for the low afﬁnity state were nearly equal for all three
receptors (nHH = 0.9–0.95 and nHL 1.4, respectively; see Table 2).nderlined and mutated amino acids are written above or below them. For numbering
Table 2
Acetylcholine afﬁnity at different ADNFLE mutants.
Receptor a EC50H nHH 1  a EC50L nHL
a4b2 19 8.4 0.9 81 77 1.4
a4 + a4S248Fb2 75 0.8 0.95 25 62 1.4
a4 + a4S252Lb2 75 0.75 0.95 25 30 1.4
a4b2 + b2L301V 56 3.8 1.3 44 41 0.9
a4b2 + b2V287M 65 0.4 1.6 35 5.3 1
a, percentage of receptors in the high-afﬁnity state; EC50H and nHH, half-maximal
effective concentration and Hill coefﬁcient for the high-afﬁnity state; EC50L and nHL,
half-maximal effective concentration and Hill coefﬁcient for the low-afﬁnity state.
O.K. Steinlein et al. / Seizure 21 (2012) 118–123 121Recorded currents of receptors carrying the b2 mutations, a4/
b2L301V and a4/b2V287M, were normalized and ﬁtted as
described above. The highest afﬁnity for ACh was seen for the
a4/b2V287M receptor (EC50H = 0.4) followed by a4/b2L301V
(EC50H = 3.8) and ﬁnally the wild type a4/b2 with the lowest
afﬁnity (EC50H of 8.4). In contrast to the alpha-subunit mutations
and to the wildtype receptors, the Hill-coefﬁcients for the high-
afﬁnity state of b2-mutations were generally higher (a4/b2L301V
nHH = 1.3; a4/b2V287M nHH = 1.6) than for the low-afﬁnity state
(L301V nHL = 0.9, V287M nHL = 1.0). The number of receptors in the
high-afﬁnity state was remarkably increased for all four mutations
examined in this study (see parameter ‘‘a’’ in Table 2).
4. Discussion
All but one of the known ADNFLE mutations cluster in small
parts of either CHRNA4 or CHRNB2 (Fig. 1), and several of these
mutations have been identiﬁed in two or more unrelated families
(Table 1). However, phenotypic comparison is hampered by the
fact that most of the published families have not been evaluated by
standardized neuropsychological tests. This renders it difﬁcult to
deduce exact risk ﬁgures for additional neurological or psychiatric
problems that might be associated with ADNFLE mutations. Mild
cognitive deﬁcits as they have been reported in a pilot study for a
small number of patients4 might often go undetected without
careful evaluation, however, major neurological symptoms such as
mental retardation or schizophrenia-like disorder are likely to be
reported. The present study therefore focused solely on such major
symptoms, but it needs to be stressed that for all mutations the
frequency of associated clinical symptoms might in fact be higher
than given in Table 1.
Comparison of the clinical data shows that the percentage of
patients reported to have associated major neurological or
psychiatric features is rather low for some mutations but quite
high for others. The data also suggest that these associations are
not exclusive as not all carriers of mutations that seem to bear an
increased risk for major neurological or psychiatric symptoms are
affected by these additional features but a few carriers of putative
low-risk mutations are. It is also interesting to note that families
carrying the same mutation tend to have an identical pattern of
accessory major neurological or psychiatric features. In some
families mental retardation was a common feature but no
psychiatric disorders were reported while in other families the
opposite pattern was observed (Table 1). The strongest association
between mutation and clinical phenotype was found for a pair of
mutations located close together in transmembrane region 2
(TM2) of CHRNA4, S248F and S252L. CHRNA4-S248F was the ﬁrst
mutation discovered in ADNFLE,1 and has been found in an
extended Australian family of British origin as well as in families
from Spain, Norway and Scotland.16–18With a total of 67 patients it
is so far the most frequently found ADNFLE mutation. The large
number of patients carrying this mutation allows a good
assessment of the clinical variability of major neurological
symptoms associated with CHRNA4-S248F. This mutation seemsto belong to the more benign causes of ADNFLE because the few
carriers that have been analysed by neuropsychological tests were
found to have mild cognitive deﬁcits [4] but major psychiatric or
neurological features other than epilepsy were only reported in
two out of 67 patients. The age of onset is within the usual range
observed for most ADNFLE mutations, and long-time remissions
are not uncommon. The rather benign nature of CHRNA4-S248F
contrasts sharply with the more severe clinical course that seems
to be associated with the adjacent mutation CHRNA4-S252L. At
least 11 of the 19 known carriers of this mutation showed
intellectual capacities that fell into the low normal or the moderate
retarded range. Remarkable is also the unusually low age of onset
which in three out of four families with CHRNA4-S252L was mostly
in early childhood (six months to two years).6,7,23 The later age of
onset in the third family argues against a causative relationship
between the early onset of epilepsy and the less than favourable
mental outcome in CHRNA4-S252L patients.8 It seems more likely
that both features are independent of each other but are both
related to the underlying mutation. Another example for two
adjacent ADNFLE mutations that differ with respect to their clinical
features is the CHRNB2 mutations V308A and I312M. Like CHRNA4-
S248F, mutation CHRNB2-V308A causes a mostly benign type of
nocturnal frontal lobe epilepsy usually without additional
neurological or psychiatric features.15 The clinical spectrum
associated with mutation CHRNB2-I312M appears to be much
more severe with all four affected members from two unrelated
families showing clinically relevant deﬁcits in their cognitive
functions, especially in verbal memory.10,24 However, unlike the
S248F and S252L mutations described above, the numbers of
families and patients with mutations V308A or I312M are still
rather low and do not allow deﬁnite conclusions about the
phenotypic differences yet.
The families carrying the same ADNFLE mutation and sharing
the same associated neurological or psychiatric features are
usually from different countries and are most likely unrelated,
thus a shared genetic background cannot explain the observed
associations. The possibility remains that the associated symptoms
are caused by a not fully penetrant mutation in a second, unknown
gene. However, the probabilities that such a gene would be
physically closely linked to the mutated nAChR gene or cose-
gregate with it in a multiplex pedigree by chance are very low,
rendering these two possibilities unlikely. Another possibility
would be that unknown environmental factors are responsible for
the increased risk for additional major features. Again, this
explanation is unlikely because the chances are very low that
the same environmental risk factors are present in families
carrying the same mutation but living in countries far apart.
Furthermore, there are no obvious differences with respect to high
drug doses or multiple drug treatment between ADNFLE families
with a high versus those with a low rate of associated clinical
features. A causal relationship between the neurological and
psychiatric features and the respective ADNFLE mutation seems to
be the most likely explanation, and it would also ﬁt well with the
wide range of neuronal dysfunctions and psychiatric disorders
nAChRs have been implicated in Ref. 26. For example, loss of
cholinergic transmission is regarded as a signiﬁcant cause of
cognitive decline in patients with Alzheimer’s disease. This
hypothesis is supported by the reduction and degeneration of
cholinergic neurons or the reduced amount of cholinergic key
enzymes like choline acetyltransferase and acetylcholine esterase
in post mortem brains of Alzheimer patients.27 More recently,
cholinergic dysfunction has been shown to be an early hallmark of
cognitive decline.28 Genetic variants in nAChR subunits have also
found to be associated with psychiatric disorders and behavioural
traits.29 It can therefore be hypothesized that the dysfunction of
nAChRs caused by ADNFLE mutations is probably at the origin of
Fig. 2. Functional properties of ADNFLE mutations. Dose response curves for controls and mutant receptors. Data points represent normalized mean values  S.E.M. Regression
curves were calculated by the sum of two empirical Hill equations. Speciﬁc values for the parameters are given in Table 2.
O.K. Steinlein et al. / Seizure 21 (2012) 118–123122the additional major neurological or psychiatric symptoms
observed in several of the patients suffering from this rare genetic
epilepsy.
Expression studies demonstrate that, despite their clustering,
ADNFLE mutations signiﬁcantly differ from each other with respect
to the changes in biopharmacological properties they induce in
receptor function. All known ADNFLE mutations have in common
that, at least in vitro, they cause a gain of function effect by
increasing the receptors sensitivity to acetylcholine.15,30 Never-
theless, the extent of this gain of function effect is not identical for
each mutation (Fig. 2), and they also display individual proﬁles for
several other biopharmacological characteristics. This is best
demonstrated for CHRNA4-S248F and CHRNA4-S252L that, coex-
pressed with wild type CHRNB2, differ from each other with respect
to their desensitisation kinetics. When ACh test-pulses were given
repeatedly while background ACh concentration was steadily
raised, nAChRs with mutation CHRNA4-S248F showed a gradual
increase of desensitisation while CHRNA4-S252L receptors pre-
sented with a nearly complete desensitisation already after the
ﬁrst test-pulse. The effect was found to be most pronounced in
experimental setups that did not include wild type CHRNA4,30
which makes it difﬁcult to predict how pronounced the effect on
desensitisation kinetics will be in vivo. Another example for
functional differences between ADNFLE mutations is CHRNB2-
V287M and CHRNB2-L301V. In the heterozygous state (CHRNB2-
V287M/CHRNB2/CHRNA4 and CHRNB2-L301V/CHRNB2/CHRNA4,
respectively) both mutations render the receptor more sensitive
towards acetylcholine, but this effect is signiﬁcantly stronger with
CHRNB2-V287M than with CHRNB2-L301V (Fig. 2). These muta-
tions display considerable differences in their EC50 values, an
observation that is more obvious in their low than in their high
afﬁnity components. These two components reﬂect the assembly
of two distinct subunit stoichiometries [a4]3[b2]2 and [a4]2[b2]3,
respectively. Taken together, the functional studies show that
ADNFLE mutations are characterized by their highly individual
biopharmacological proﬁles, but mutations that are frequently
associated with additional major symptoms do not necessarily
display larger functional changes than mutations that cause a more
‘‘benign’’ course of the disorder. So far no direct correlation has
been found between the impact an ADNFLE mutation has on
receptor function and the severity of the clinical symptoms.5. Conclusions
The data presented here suggest that certain ADNFLE mutations
might be associated with speciﬁc risks for additional major
neurological or psychiatric symptoms. However, the numbers of
affected families are still too low for some of these mutations and
many of the families included here did not yet underwent a
comprehensive neuropsychological examination. Clinicians who
evaluate patients from ADNFLE families should therefore include
neuropsychological testing whenever possible in order to increase
our knowledge about the genotype-phenotype correlations in this
rare disorder.
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